Objective-To compare the first dose responses to low dose angiotensin converting enzyme inhibitors (captopril, enalapril, and perindopril) in elderly patients with stable chronic heart failure. Design-Double blind, randomised, placebo controlled, parallel, group prospective study of elderly patients with stable chronic heart failure.
responses to low dose angiotensin converting enzyme inhibitors (captopril, enalapril, and perindopril) in elderly patients with stable chronic heart failure.
Design-Double blind, randomised, placebo controlled, parallel, group prospective study of elderly patients with stable chronic heart failure.
Setting-General hospital in-patient admissions for supervised diuretic withdrawal (24-48 hours) and the introduction of angiotensin converting enzyme inhibitor therapy.
Patients-48 unselected elderly (58-85 years) patients with symptomatic but stable chronic heart failure (New York Heart Association grades II-IV) confirmed by clinical history, examination, and cardiological investigations. Patients gave their written and informed consent to receive their initial treatment under double blind conditions; blood pressure was monitored and blood samples taken to measure the pharmacokinetic and neurohormonal responses.
Intervention-Patients were randomised to receive a daily oral dose of placebo, captopril (6 25 mg), enalapril (2 5 mg), or perindopril (2 mg).
Main outcome measures-Blood pressure and heart rate responses, drug concentration, and plasma renin and ACE activities. Differences between treatment groups were analysed by analysis of variance.
Results-The four randomised groups of patients had similar age, severity of heart failure (NYHA class), pretreatment diuretic dosage, plasma renin activity, and serum electrolyte state.
Placebo treatment caused a modest but significant diurnal fall in blood pressure.
Captopril produced a significant early (1-5 hours) and brief fall in blood pressure. The blood pressure fall with enalapril was later (4-10 hours), longer lasting, and was associated with significant slowing of supine heart rate. Though perindopril produced a similar plasma ACE inhibition to that produced by enalapril, it only caused changes in blood pressure that were similar to those caused by placebo.
Conclusions-This controlled study is the first to indicate a qualitative difference in the acute response to angiotensin converting enzyme inhibitors with similar structure and metabolism (that is, enalapril and perindopril). Low dose perindopril seems to be less likely to cause hypotension in patients with heart failure. The explanation for the differences is unclear but may reflect differential effects on local tissue angiotensin generation.
Several angiotensin converting enzyme (ACE) inhibitors have been shown to be valuable in the management of chronic heart failure."q They relieved symptoms, improved haemodynamic function, and reduced the associated mortality regardless of the aetiology of the syndrome. Efficacy has been well documented for moderate to severe chronic heart failure (New York Heart Association (NYHA) grades III-IV) and more recent studies suggest benefit in milder disease.5 In most instances treatment with ACE inhibitors has been studied as an adjunct to diuretic and in some instances digoxin treatment. A series of case reports and small studies showed a considerable fall in blood pressure in response to the first dose of ACE inhibitor in patients with mild heart failure.6 The origins of this response remain unclear. It may partly reflect activation of the circulating and tissue based renin angiotensin system either as a response to chronic heart failure7 or to preceding or concurrent diuretic treatment. Four study groups (n = 12) were given oral captopril 6-25 mg, oral enalapril 2-5 mg, oral perindopril 2 mg, or oral placebo (lactose) within an opaque gelatin capsule. Table 1 shows the characteristics of the four groups. The study protocol was approved by the local research and ethics review committee. All patients gave their written and informed consent to take part in the study. After oral dosing blood pressure was measured in supine patients every 2 minutes with additional triplicate determinations at set time points. Blood samples were withdrawn frequently to determine the pharmacokinetic profile, ACE activity, and renin activity. Patients remained supine and received their normal meals throughout the study until 10 hours after dosing. Then they were allowed to rise but they were supine for at least 45 minutes before further blood sampling and blood pressure recordings at 24 hours after dosing. After this the nature of treatment was decoded and further treatment was arranged including re-instatement of diuretics and vasodilators at the discretion of the clinical staff. Patients receiving placebo continued on diuretic withdrawal and received open captopril with conventional observation on the ward. These patients were not included in any other active treatment group.
LABORATORY AND STATISTICAL ANALYSIS
We used high pressure liquid chromotography to measure the drug concentration and plasma ACE activity from the production of hippuric acid released from the exogenous substrate Hip-His-Leu." Owing to the special sample preparation required with captopril to avert in vitro dimer formation and dissociation from ACE neither drug concentrations nor ACE activity could be assessed in the captopril group. Plasma renin activity was assessed by generation of angiotensin II from exogenous angiotensin I measured by radio- 12-8) ). In addition, the baseline supine heart rate was significantly lower (p < 0 05) in the group who were treated with captopril (75 9 (9 8) beats/minute) than in those who received enalapril (83-3 (15-9)), perindopril (77-1 (104)), or placebo (81-1 (12 8)). For these reasons the temporal pattern of response was described as the change from individual baseline pressures and heart rate rather than absolute values. This did not materially alter the general trends and the statistically significant differences. Mean arterial pressure fell during placebo treatment by approximately 10 mm Hg over the first 4-5 hours. Compared with the other treatments, captopril produced a significant fall in blood pressure (trough at 1-5 hours). Blood pressure had largely returned to normal by six hours. Enalapril produced a smooth and protracted fall in mean arterial pressure that was significantly greater than that produced by placebo from two to five hours (maximum at four to five hours post-dosing). Pressure remained significantly depressed at 10 hours. In contrast, after perindopril the mean arterial pressuredidnotsignificantlydifferfromplacebo throughout the period of study ( fig 1A) . The individual maximum fall in mean arterial pressure from baseline was calculated. The mean maximum fall in the perindopril group (-15 1 (8 2), range -2 to -30 1 mm Hg) was similar to that seen with placebo (-16 4 (7 7), range -4 to -31 9 mm Hg). The mean maximum fall in mean arterial pressure for both the captopril (-22-4 (11-6), range -14 to -45 7) and enalapril (-26-4 (7 5), range -13-8 to -43) groups was significantly greater (p = 0-012).
Baseline corrected changes in mean supine heart rate were small in absolute terms. However, the group treated with enalapril showed a significant fall between one and eight hours after dosing (-10-8 (7 2) beats/minute) compared with placebo (-2 0 (9 6) beats/ minute). This was not evident with captopril or perindopril ( fig 1B) . ACE therefore reflect an important and relevant agent-specific difference iI between ACE inhibitors. The comp performed in patients who remained controlled hospital setting. The a blood pressure response would be e follow a similar pattern. At the dos there was a similar differential respor rate. Altered autonomic tone and ba reflexes in patients in heart failur known20 as are the antiadrenergic or pathomimetic properties of c enalapril,22 and perindopril.23 To our knowledge this is the first demonstration of a small but significant slowing of basal heart rate in a study of supine patients after low dose enalapril with an appropriate placebo control group. This effect on heart rate was seen only briefly with captopril and not seen at all with perindopril.
One of the proposed mechanisms for the fall in blood pressure in a proportion of heart failure patients treated with ACE inhibitors is activation of the Bezhold-Jarisch reflex by vagally mediated hypotension and bradycardia.24 One of our patients had a considerable fall in blood pressure and associated bradycardia yet remained symptom free immediately after a dosing with placebo ( fig 5) . He subsequently tolerated open captopril therapy on the following day without complications. His placebo response was not excluded from our analysis. This reflex mechanism may be relevant in a few reported cases of hypotension after ACE inhibitors in heart failure patients. The BezholdJarisch reflex clearly has little relevance to specific ACE inhibitors, agent selection, or general management policies designed to avoid hypotension in heart failure because it is unpredictable and not related to dose or to individual drugs. 
